Patent on packaged modified release gamma-hydroxybutyrate formulations having improved stability

Packaged modified release gamma-hydroxybutyrate formulations improve stability and simplify treatment. The patent WO2019123269A1, titled “Packaged modified release gamma-hydroxybutyrate formulations having improved stability,” introduces innovative formulations and packaging methods. These methods enhance both dissolution and chemical stability of gamma-hydroxybutyrate (GHB), a therapy for narcolepsy. Currently, treatments like XYREM® force patients to wake during the night for a second dose, which proves cumbersome. Therefore, this patent develops a once-nightly, modified-release GHB formulation. Moreover, advanced packaging controls relative humidity, ensuring long-term effectiveness and preventing chemical degradation of GHB into gamma-butyrolactone (GBL).

Key Innovations:

1. Modified Release Formulation: The patent combines immediate and modified release components, both containing GHB or a pharmaceutically acceptable salt. The modified release component controls GHB release over time. As a result, it provides sustained therapeutic effects throughout the night. Therefore, patients do not need a second dose. Consequently, this formulation improves convenience and supports adherence to treatment.
2. Stability Issues with GHB: GHB is highly hygroscopic and chemically unstable. Consequently, it degrades easily, especially in high-humidity environments. This degradation produces GBL, which reduces the drug’s effectiveness. Therefore, the patent develops a formulation with stable dissolution profiles and improved chemical stability. Moreover, it maintains stability even under stressful storage conditions, such as high temperature and humidity.
3. Packaging Innovation: To enhance stability, the GHB formulations use packaging that maintains a specific relative humidity range (29% to 54%). This control of humidity is crucial because it prevents GHB from degrading into GBL. Moreover, the packaging material has a low water vapor transmission rate. As a result, it reduces moisture exposure and ensures the drug stays stable over time.
4. Hydrophobic Coating: The patent applies a hydrophobic coating, such as glyceryl tristearate or hydrogenated vegetable oil, along with methacrylic acid copolymers. These coatings control the release rate of GHB. Moreover, they protect it from moisture. As a result, the formulation provides a steady release and prevents premature degradation.
5. Pharmaceutical Composition: The GHB composition includes varying ratios of immediate and modified release components. These ratios ensure a sufficient therapeutic dose while maintaining stability. Moreover, particle size and formulation ratios (e.g., 40/60 to 60/40) play key roles in achieving the desired pharmacokinetics and release profiles.

Controlling the relative humidity within the packaging

The primary innovation lies in controlling the relative humidity within the packaging, alongside a modified release formulation with hydrophobic coatings to maintain the drug’s chemical stability and effectiveness. These advancements make GHB therapy more convenient by eliminating the need for a second nightly dose and addressing the stability challenges that have plagued previous formulations.

In this patent, CELLETS® play a crucial role as inert cores used in the formulation of modified release or the active or salts thereof. These starter spheres serve as carriers for the active ingredient by providing a surface for multi-layer drug layering. Their primary function is to ensure uniform drug distribution and control the release profile of GHB. The benefits include enhancing dissolution stability, maintaining the integrity of the dosage form over time, and helping to modulate the release rate of the drug for once-nightly dosing convenience. For these aspects, MCC starter sphere types where employed: CELLETS® 90, CELLETS® 100, CELLETS® 127. Glatt ProCell™ technique is used for spraying molten API.

Document information

Disclaimer

This text was partly generated by chatGPT engine version GPT‑4o, on Oct 21, 2024. Image was generated with Adobe Firefly.